Curi Bio Acquires CarTox™ Technology from StemBioSys, Announces Launch of Nautilus™ Optical Mapping System
Summary
With the ability to quantify action potential duration, calcium transients, triangulation, and other key electrophysiological metrics, the platform allows users to collect comprehensive 2D and 3D data sets for their drug discovery and screening, all in standard SBS-compliant plate formats. The Nautilus system was also featured in a Nature Scientific Reports publication entitled, "Human perinatal stem cell derived extracellular matrix enables rapid maturation of hiPSC-CM structural and functional phenotypes” by Block et al. The platform enabled high throughput cardiotoxicity screening of human cardiomyocytes utilizing reference compounds recommended for the evolving Comprehensive In Vitro Proarrhythmia Assay (CiPA) coordinated by the Health and Environmental Sciences Institute (HESI). The paper was published as a collaboration between the lab of Dr. Todd Herron, Director of the Frankel Cardiovascular Regeneration Core Laboratory at the University of Michigan, and StemBioSys, which was awarded a Phase II SBIR grant from the NIH. Event: Society of Toxicology 2022 Date: Tuesday, March 29, 2022 at 10:30 am PDT Session Title: High-throughput Assessment of Cardiac Safety via Contractility Measurements of 3D Engineered Heart Tissues To learn more about how the Nautilus system can improve the predictive power of your experiments, or about Curi’s other human-relevant preclinical platform technologies and services, please reach out at www.curibio.com/contact.